Interferon Versus the Allograft

This flow traces the confrontation between antiviral treatment after transplantation and the risk of interferon-induced rejection.

increasingBearing stren­gth in each eventdecreasing

Pretransplant Safety

Pretransplant Safety The preferred timing Interferon-based treatment is safer before transplantation because there is no graft for immune activation to attack. Viral clearance at this stage may prevent later glomerular disease. A strategic advantage The patient can accept treatment toxicity without risking acute allograft rejection. Timing becomes as important as drug choice.

Posttransplant Rejection

Posttransplant Rejection Immune activation Interferon can upregulate cytokines and HLA-related responses, provoking Acute rejection or graft dysfunction. Historical series report frequent interruption of treatment for renal deterioration. Therapeutic prohibition For this reason, interferon is generally contraindicated after kidney transplantation except in severe, life-threatening HCV disease. The kidney graft transforms a potentially useful antiviral into a dangerous immunologic trigger.

Exceptional Use

Exceptional Use When avoidance fails Severe liver fibrosis, Fibrosing cholestatic hepatitis, or serious HCV-related graft disease may justify antiviral treatment despite rejection risk. The indication arises from immediate danger rather than routine prevention. A calculated sacrifice The patient and clinicians accept uncertainty because untreated disease may be fatal. Treatment becomes a rescue maneuver in which graft preservation is no longer the only goal.

before Kidney transplantation

during posttransplant interferon treatment

during Fibrosing cholestatic hepatitis or severe posttransplant disease